Drugs / TAS-106
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00752011 | Jun 2008 → Oct 2012 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00737360 | Aug 2008 → Jun 2011 | head and neck cancer | Taiho Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS-106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00737360 ↗ |
| Known as | 2'-c-ethynylcytidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL573352 ↗ |
| Known as | 3'-c-ethynylcytidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL573352 ↗ |
| Action | Inhibit | “DNA-directed RNA polymerase III subunit RPC1 inhibitor” CHEMBL573352 ↗2“DNA-directed RNA polymerase II subunit RPB1 inhibitor” CHEMBL573352 ↗ “DNA-directed RNA polymerase I subunit RPA1 inhibitor” CHEMBL573352 ↗ |
| Modality | Small molecule | — CHEMBL573352 ↗ |
| Route | Intravenous | “6.5 mg/m2, IV on day 1 of each 21 day cycle.” NCT00737360 ↗ |
| Target | POLR1A | “DNA-directed RNA polymerase I subunit RPA1 inhibitor” CHEMBL573352 ↗ |
| Target | POLR2A | “DNA-directed RNA polymerase II subunit RPB1 inhibitor” CHEMBL573352 ↗ |
| Target | POLR3A | “DNA-directed RNA polymerase III subunit RPC1 inhibitor” CHEMBL573352 ↗ |